Skip to main content

Certara to Participate in the Jefferies Global Healthcare Conference

PRINCETON, N.J.— June 2, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference. Company management will present at 1:30PM ET on Wednesday, June 7th, 2023. A live webcast of the event will be available on Certara’s investor relations website at … Continued

Certara Reports First Quarter 2023 Financial Results

Reiterates 2023 Financial Guidance PRINCETON, N.J.— May 8, 2023– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. First Quarter Highlights: “We are pleased with our first quarter financial results and performance in software and biosimulation services” said William F. Feehery, chief … Continued

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year

Asserts Certara’s leadership in advancing the development and approval of new drugs for patients PRINCETON, N.J.— April 27, 2023 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received … Continued

Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference

PRINCETON, N.J.— April 10, 2023– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening … Continued

A.I. Coming to Certara’s D360 Scientific Informatics Software

New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses PRINCETON, NJ March 9 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform. The addition of novel A.I. will enable discovery scientists … Continued

Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types

Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies PRINCETON, N.J.— March 7, 2023 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based … Continued

Certara Reports Fourth Quarter and Full Year 2022 Financial Results

Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency PRINCETON, N.J.— March 1, 2023– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2022 and issued guidance for 2023. Fourth Quarter Highlights: Full Year Highlights: “We are pleased … Continued

Certara Announces Transition Plan For Chief Financial Officer

PRINCETON, N.J. – March 1, 2023 – Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023.  Mr. Schemick will transition into a newly created position as Senior Vice President, Corporate Operations and Integration, and he will be focused on supporting John’s transition, and … Continued

Certara to Participate in the Barclays Global Healthcare Conference

PRINCETON, N.J.— February 27, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healthcare Conference. Company management will present at 11:15AM ET on Wednesday, March 15th, 2023. A live webcast of the event will be available on Certara’s investor relations website at … Continued

2 of 33